Unilateral Biportal Endoscopy Market Size, Share & Trends Analysis Report By Product (Reusable, Single-Use), By Application (Decompression, Deherniation), By End Use, By Region, And Segment Forecasts, 2025 - 2030

Unilateral Biportal Endoscopy Market Size, Share & Trends Analysis Report By Product (Reusable, Single-Use), By Application (Decompression, Deherniation), By End Use, By Region, And Segment Forecasts, 2025 - 2030

Self-injection Devices Market Growth & Trends

The global self-injection devices market size is expected to reach USD 40.50 billion by 2030, registering a CAGR of 10.31% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing patient volume and rising prevalence of chronic diseases along with the high adoption of advanced drug delivery systems are factors estimated to surge the demand for self-injection devices.

Prevention of needlestick injury is a primary factor for healthcare professionals and companies to introduce self-injection devices such as autoinjectors. To avoid needlestick injuries to healthcare workers, the U.S., Europe, and other markets mandate the use of safety devices. Several auto-injectors provide the additional benefit of needlestick protection to healthcare professionals. It is expected that in the U.S. about 69,000 injuries can be prevented annually. Numerous auto-injectors have integral and passive safety features that eliminate or reduce the risk of injury.

Innovation in the field of New Drug Delivery Systems (NDDDS) has led to the rising demand for self-administered medications. The invention of novel injectable delivery devices such as pre-filled syringes, pen injectors, autoinjectors, and needle-free injectors has made the self-administration of drugs easier and more convenient for patients. The majority of biological drugs are delivered using injections, which include the threat of needlestick injuries. To minimize this issue, pharmaceutical firms are developing self-administered needle-free injectors and patient-friendly medication-device combination products.

The COVID-19 pandemic has altered expectations and perceptions of delivery settings and contributed to a rise in preference for self-administration medication. As this becomes the norm, several manufacturers are inclined to make the patient experience the vital component of drug delivery design. Significantly, the COVID-19 vaccines will increase the demand for injectable devices and the pandemic has also shown the benefit of self-use devices as well as connected devices. Post-pandemic there may be a rise in upcoming innovation in devices and pharma manufacturers will progressively collaborate to use self-injection devices in combination with other digital assets such as apps, phones, and personal computers. Eventually, this will bring the patient into far greater control of their care.

Self-injection Devices Market Report Highlights

• The market is classified by product into auto-injectors, pen injectors, wearable injectors, and needle-free injectors. The needle-free injector segment held the largest share, accounting for around 28.32% of the market in 2024, due to its high effectiveness and adoption rates worldwide.
• Based on usability, the market is segmented into reusable and disposable. The disposable segment held around 62.64% market share in 2024.
• The market is segmented by application into cancer, pain management, autoimmune disorders, hormonal disorders, and others. Cancer is among the leading segments, holding around 26.82% market share in 2021.
• North America self-injection devices market dominated the overall global market and accounted for 42.44% of revenue share in 2024. The North American market is driven by several factors, including increased preference of the patients toward self-medication, increasing cancer cases, and rising cases of hormonal diseases.
• The Asia Pacific self-injection devices market is experiencing substantial growth, primarily driven by rapidly advancing healthcare infrastructure in key countries such as India, China, and Japan, alongside increasing investments in treating chronic disorders.

Please note The report will be delivered in 2-3 business days upon order notification.